These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7541527)

  • 1. Assay variability in serum prostate-specific antigen determination.
    Brawer MK; Daum P; Petteway JC; Wener MH
    Prostate; 1995 Jul; 27(1):1-6. PubMed ID: 7541527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
    Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
    Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.
    Oesterling JE; Moyad MA; Wright GL; Beck GR
    Urology; 1995 Oct; 46(4):524-32. PubMed ID: 7571222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some analytical considerations on the measurement of prostate-specific antigen.
    Blijenberg BG; Kranse R; Eman I; Schröder FH
    Eur J Clin Chem Clin Biochem; 1996 Oct; 34(10):817-21. PubMed ID: 8933105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability analysis of first and second generation PSA assays.
    Wymenga LF; Groenier K; Visser-van Brummen P; Marrink J; Mensink HJ
    Can J Urol; 2000 Aug; 7(4):1070-6. PubMed ID: 11109077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy.
    van Iersel MP; Thomas CM; Segers MF; Witjes WP; Debruyne FM; Oosterhof GO
    Br J Urol; 1996 Mar; 77(3):418-22. PubMed ID: 8814849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen.
    Vessella RL; Noteboom J; Lange PH
    Clin Chem; 1992 Oct; 38(10):2044-54. PubMed ID: 1382897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in measurement of prostate-specific antigen: importance of method and lot variability.
    Wener MH; Daum PR; Brawer MK
    Clin Chem; 1995 Dec; 41(12 Pt 1):1730-7. PubMed ID: 7497613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay.
    Klee GG; Dodge LA; Zincke H; Oesterling JE
    J Urol; 1994 Jan; 151(1):94-8. PubMed ID: 7504749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method.
    Brawer MK; Bankson DD; Haver VM; Petteway JC
    Prostate; 1997 Mar; 30(4):269-73. PubMed ID: 9111605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSYM assays.
    Leewansangtong S; Goktas S; Lepoff R; Holthaus K; Crawford ED
    Urology; 1998 Sep; 52(3):467-9. PubMed ID: 9730462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abbott IMx evaluated for assay of prostate-specific antigen in serum.
    Dnistrian AM; Schwartz MK; Smith CA; Nisselbaum JS; Fair WR
    Clin Chem; 1992 Oct; 38(10):2140-2. PubMed ID: 1382898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free and total prostate-specific antigen in a screened population.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Br J Urol; 1997 May; 79(5):756-62. PubMed ID: 9158515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen.
    Jacobsen SJ; Lilja H; Klee GG; Wright GL; Pettersson K; Oesterling JE
    Urology; 1994 Oct; 44(4):512-8. PubMed ID: 7524236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 3 investigational assays for the free form of prostate specific antigen.
    Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
    J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay.
    Schild SE; Wong WW; Novicki DE; Ferrigni RG; Swanson SK
    Urology; 1996 Jun; 47(6):878-81. PubMed ID: 8677580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist.
    Hofer C; Sauerstein P; Wolter C; Scholz M; Hartung R; Breul J
    Urol Int; 2000; 64(1):18-23. PubMed ID: 10782027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variation of percent free prostate-specific antigen determined by two different assays.
    Yang CR; Ou YC; Horng YY; Lee HS
    Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
    Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
    Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.